摘要:
This invention comprises a process for cracking a hydrocarbon charge stock using a used FCC catalytic composite comprising a zeolitic crystalline aluminosilicate dispersed in a porous inorganic matrix. Particles of zeolitic crystalline aluminosilicate having diameters less than the diameters of the pores of the composite are impregnated into the composite preferably by contacting the composite with an aqueous slurry of the particles and the evaporating off the water of the slurry.
摘要:
A method of increasing the activity and selectivity of a regenerated used FCC catalytic composite comprising a zeolitic crystalline aluminosilicate dispersed in a porous inorganic oxide matrix, the resultant composite and a cracking process utilizing the resultant composite. Particles of zeolitic crystalline aluminosilicate having diameters less than the diameters of the pores of the composite are impregnated into the composite, preferably by contacting the composite with an aqueous slurry of the particles and then evaporating off the water of the slurry.
摘要:
Implants and methods for treating ocular disorders are disclosed. One implant has a tubular member, with inlet and outlet ends, and a cutting member connected thereto. The tubular member is configured to extend through eye tissue such that the inlet and outlet ends reside respectively in an anterior chamber and a physiologic outflow pathway of the eye. Desirably, the cutting member is configured to make an incision in the eye tissue for receiving at least a portion of the tubular member. One method involves introducing an implant, with proximal and distal ends, into the anterior chamber and penetrating eye tissue using an implant distal portion. The implant is advanced from the anterior chamber into the penetrated eye tissue to locate the distal and proximal ends respectively in the physiologic outflow pathway and the anterior chamber. Aqueous humor is conducted between the proximal and distal ends.
摘要:
The invention discloses a pharmaceutical composition of liposome nanoparticles for lodging in a target tissue cell in situ of an animal subject, the nanoparticles comprising at least one thermal triggered phase-transition compound as a targeting drug delivery system for physical cancer therapy.
摘要:
A medical device and methods to relieve joint pain and adapted for knee joint repair, replacement and augmentation. The invention discloses joint lubricant, particularly hyaluronate compositions and methods for treatment of osteoarthritis.
摘要:
The invention relates to a pharmaceutical composition of nanoparticles, wherein the nanoparticles comprise positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent for treating diabetes of an animal subject.
摘要:
A gastric space filler device for treating obesity in a patient by reducing the stomach volume features at least one inflatable space filler with drag delivery and stimulation features and includes therapeutic devices and anchoring apparatus enabling tracking, visualization and optimized management of inter-balloon connecting sections, drug reservoirs and pumping systems along with related improvements.
摘要:
The invention discloses particulate complexes composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein equal moles of the positively charged chitosan and the negatively charged poly-glutamic acid substrate form an electrostatic network enabling improved loading the bioactive agent.
摘要:
The invention relates to a method of co-administering a peptide or protein drug with an enzyme-resistant PGA-complexone compound orally so to mitigate enzyme attack in the gastrointestinal tract of an animal subject.
摘要:
A method is provided for treatment of cataract in combination with a glaucoma procedure while maintaining the intraocular pressure by permitting aqueous to flow out of an anterior chamber of the eye through a surgically stented pathway. A trabecular stent is adapted for implantation within the trabecular meshwork of an eye such that intraocular liquid flows controllably from the anterior chamber of the eye to Schlemm's canal, bypassing the trabecular meshwork. Depending upon the specific treatment contemplated, pharmaceuticals may be utilized in conjunction with the trabecular stent enabling post-cataract healing processes.